Table 3.
Studies evaluating cDCD SLKT and LT outcomes: patient and graft survival
| Author, date | Arms (Number of recipients and donor type) | 1-year patient survival (%) | 1-year liver allograft survival (%) | 1-year kidney allograft survival (%) | 3-years patient survival (%) | 3-years liver allograft survival (%) | 3-years kidney allograft survival (%) |
|---|---|---|---|---|---|---|---|
| STUDIES EVALUATING cDCD VERSUS DBD IN SLKT | |||||||
| Nunez-Nateras et al., 2020 [45] | 30 cDCD SLKT | 96.7 | 93.3 | 93.3 | 93.3 | 90.0 | 90.0 |
| 131 DBD SLKT | 95.4 | 93.1 | 93.1 | 93.3 | 90.1 | 90.1 | |
| Croome et al., 2020 [46] | 94 cDCD SLKT (Era 1) | 72.9 | 69.2 | 67.4 | 64.8 | 59.5 | 58.4 |
| 208 cDCD SLKT (Era 2) | 87.6 | 83.1 | 86.5 | 82.4 | 76.6 | 79.4 | |
| 624 DBD SLKT (propensity matched) (Era 2) | 91.3 | 90.4 | 88.6 | 83.4 | 82.3 | 81.5 | |
| LaMattina et al., 2011 [47] | 5 cDCD SLKT | 100 | 100 | 100 | * | * | * |
| 32 DBD SLKT | 97 | 94 | 94 | * | * | * | |
| STUDIES EVALUATING NRP VERSUS SRR IN cDCD LT | |||||||
| Hessheimer et al., 2019 [60] | 95 NRP cDCD LT | 93 | 88 | / | 93 | 88 | / |
| 117 SRR cDCD LT | 88 | 83 | / | 84 | 76 | / | |
| Watson et al., 2019 [51] | 43 NRP cDCD LT | 97 | 98 | / | 94 | 93 | / |
| 187 SRR cDCD LT | 95 | 87 | / | 93 | 85 | / | |
| Hessheimer et al., 2022 [50] | 545 NRP cDCD LT | 92 | 90 | / | 89 | 87 | / |
| 258 SRR cDCD LT | 86 | 79 | / | 76 | 68 | / | |
| STUDIES EVALUATING NRP cDCD VERSUS DBD IN LT | |||||||
| Savier et al., 2020 [52] | 50 NRP cDCD LT | 97 | 95 | / | 83 | 80 | / |
| 100 DBD LT | 90 | 88 | / | 84 | 82 | / | |
| STUDIES EVALUATING NP VERSUS SCS IN LT | |||||||
| Nasralla et al., 2018 [56] | 170 NP LT (107 DBD and 63 cDCD) | 96 | 95 | / | * | * | / |
| 164 SCS LT (104 DBD and 60 cDCD) | 97 | 96 | / | * | * | / | |
| STUDIES EVALUATING HOPE VERSUS SCS IN LT | |||||||
| Schlegel et al., 2019 [61] | 50 HOPE cDCD LT | 98 | 92 | / | 94 | 92 | / |
| 50 SCS cDCD LT | 90 | 88 | / | 88 | 80 | / | |
| 50 SCS DBD LT | 92 | 88 | / | 92 | 88 | / | |
| Czigany et al., 2021 [62] | 23 HOPE ECD DBD LT | 91 | 91 | / | * | * | / |
| 23 SCS ECD DBD LT | 83 | 78 | / | * | * | / | |
| Schlegel et al., 2023 [57] | 85 HOPE DBD LT | 95.3 | 95.3 | / | * | * | / |
| 85 SCS DBD LT | 95.3 | 91.8 | / | * | * | / | |
| STUDIES EVALUATING NRP VERSUS HOPE IN cDCD LT | |||||||
| Muller et al., 2020 [58] | 132 NRP cDCD LT | 95 | 93 | / | 92 | 88 | / |
| 93 HOPE cDCD LT | 93 | 86 | / | 90 | 83 | / | |
| STUDIES COMPARING NRP VERSUS NP IN cDCD LT | |||||||
| Mohkam et al., 2022 [63] | 34 NP cDCD LT | 94.1 | 88.2 | / | * | * | / |
| 68 NRP cDCD LT | 98.5 | 93.9 | / | * | * | / | |
| Gaurav et al., 2022 [59] | 69 NRP cDCD LT | 94.0 | 93.0 | / | 94.0 | 90.0 | / |
| 67 NP cDCD LT | 94.0 | 88.0 | / | 90.0 | 76.0 | / | |
| 97 SCS cDCD LT | 94.0 | 84.0 | / | 88.0 | 76.0 | / | |
SLKT Simultaneous Liver-Kidney Transplantations; LT: Liver Transplantation; KT: Kidney Transplantation; DBD: Donation after Brain Death; cDCD: Controlled Donation after Circulatory Death; NP: Ex-Situ Normothermic Perfusion; NRP: Normothermic Regional Perfusion; SCS: Static Cold Storage; SRR: Super-Rapid Recovery; HOPE: Ex-Situ Hypothermic Oxygenated Perfusion; ECD: Extended Criteria Donors